NO951593L - Nye substituerte azetidinoner som antiinflammatoriske og antidegenerative midler - Google Patents

Nye substituerte azetidinoner som antiinflammatoriske og antidegenerative midler

Info

Publication number
NO951593L
NO951593L NO951593A NO951593A NO951593L NO 951593 L NO951593 L NO 951593L NO 951593 A NO951593 A NO 951593A NO 951593 A NO951593 A NO 951593A NO 951593 L NO951593 L NO 951593L
Authority
NO
Norway
Prior art keywords
chem
inflammatory
substituted azetidinones
newly substituted
degenerative agents
Prior art date
Application number
NO951593A
Other languages
English (en)
Other versions
NO951593D0 (no
NO305697B1 (no
Inventor
Soumya P Sahoo
Jeffrey J Hale
Thomas J Lanza
William K Hagmann
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO951593D0 publication Critical patent/NO951593D0/no
Publication of NO951593L publication Critical patent/NO951593L/no
Publication of NO305697B1 publication Critical patent/NO305697B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO951593A 1992-10-27 1995-04-26 Nye, substituerte azetidinoner som antiinflammatoriske og antidegenerative midler NO305697B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US99183892A 1992-12-17 1992-12-17
PCT/US1993/010268 WO1994010142A1 (en) 1992-10-27 1993-10-26 New substituted azetidinones as anti-inflammatory and antidegenerative agents

Publications (3)

Publication Number Publication Date
NO951593D0 NO951593D0 (no) 1995-04-26
NO951593L true NO951593L (no) 1995-06-23
NO305697B1 NO305697B1 (no) 1999-07-12

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951593A NO305697B1 (no) 1992-10-27 1995-04-26 Nye, substituerte azetidinoner som antiinflammatoriske og antidegenerative midler

Country Status (29)

Country Link
EP (1) EP0595557B1 (no)
JP (1) JPH082868B2 (no)
KR (1) KR950704250A (no)
CN (1) CN1043884C (no)
AT (1) ATE270273T1 (no)
AU (1) AU663806B2 (no)
CA (1) CA2108584C (no)
CY (1) CY2529B1 (no)
CZ (1) CZ106895A3 (no)
DE (1) DE69333563T2 (no)
DK (1) DK0595557T3 (no)
DZ (1) DZ1724A1 (no)
ES (1) ES2224095T3 (no)
FI (1) FI951992A0 (no)
HR (1) HRP931309A2 (no)
HU (2) HUT72084A (no)
IL (1) IL107321A (no)
LV (1) LV13338B (no)
MX (1) MX9306666A (no)
MY (1) MY128261A (no)
NO (1) NO305697B1 (no)
NZ (1) NZ257755A (no)
PL (1) PL308545A1 (no)
PT (1) PT595557E (no)
RU (1) RU2148056C1 (no)
SI (1) SI9300566A (no)
SK (1) SK53795A3 (no)
TW (1) TW275621B (no)
WO (1) WO1994010142A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
WO1996029307A1 (fr) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
JP3081250B2 (ja) * 1995-10-31 2000-08-28 メルク エンド カンパニー インコーポレーテッド 置換アゼチジノンの製造方法
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
WO2000005204A1 (fr) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
JP5111657B2 (ja) * 2009-03-09 2013-01-09 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペラジン化合物
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
JPH082868B2 (ja) 1996-01-17
LV13338B (en) 2006-01-20
IL107321A0 (en) 1994-01-25
JPH06263723A (ja) 1994-09-20
RU95109936A (ru) 1997-01-10
HRP931309A2 (en) 1997-02-28
MY128261A (en) 2007-01-31
HU9501184D0 (en) 1995-06-28
WO1994010142A1 (en) 1994-05-11
PL308545A1 (en) 1995-08-21
NO951593D0 (no) 1995-04-26
KR950704250A (ko) 1995-11-17
EP0595557B1 (en) 2004-06-30
AU663806B2 (en) 1995-10-19
SK53795A3 (en) 1995-09-13
DE69333563T2 (de) 2005-08-18
CA2108584C (en) 1998-11-24
PT595557E (pt) 2004-10-29
EP0595557A1 (en) 1994-05-04
SI9300566A (en) 1994-09-30
DZ1724A1 (fr) 2002-02-17
FI951992A (fi) 1995-04-26
ATE270273T1 (de) 2004-07-15
MX9306666A (es) 1994-04-29
AU5028393A (en) 1994-05-12
CY2529B1 (en) 2006-04-12
CN1090272A (zh) 1994-08-03
NZ257755A (en) 1998-03-25
HU211619A9 (en) 1995-12-28
DK0595557T3 (da) 2004-10-25
FI951992A0 (fi) 1995-04-26
CN1043884C (zh) 1999-06-30
DE69333563D1 (de) 2004-08-05
CZ106895A3 (en) 1996-03-13
HUT72084A (en) 1996-03-28
TW275621B (no) 1996-05-11
RU2148056C1 (ru) 2000-04-27
IL107321A (en) 1998-08-16
CA2108584A1 (en) 1994-04-28
ES2224095T3 (es) 2005-03-01
NO305697B1 (no) 1999-07-12

Similar Documents

Publication Publication Date Title
CY2529B1 (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
NO307047B1 (no) Nye hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere, farmasøytisk preparat inneholdende slike, og anvendelse derav
BR9206623A (pt) Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
FI895185A0 (fi) Mevalonolaktoner av tienopyridintyp.
NO933837L (no) 4-aryl-3-(heteroarylureido)kinolin-derivater
FI960206A (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
ATE207486T1 (de) Quinolin-derivate
PT89492A (pt) Processo de preparacao de novos derivados de tioformamida terapeuticamente activos

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2002